Sadikan Muhammad Zulfiqah, Lambuk Lidawani, Reshidan Nur Hidayah, Abdul Ghani Nurliyana Ain, Ahmad Azral Ismawy, Ahmad Kamal Mohd Saleh, Lazaldin Mohd Aizuddin Mohd, Ahmad Hairi Haryati, Mohamud Rohimah, Abdul Nasir Nurul Alimah
Faculty of Medicine, Department of Pharmacology, Manipal University College Malaysia (MUCM), Melaka, Malaysia.
Department of Immunology, School of Medical Sciences, Universiti Sains Malaysia, Kelantan, Malaysia.
J Ocul Pharmacol Ther. 2025 Apr;41(3):150-161. doi: 10.1089/jop.2024.0123. Epub 2025 Feb 3.
Age-related macular degeneration (AMD) poses a significant threat to visual health among the elderly, necessitating urgent preventive measures as the global population ages. Extensive research has implicated oxidative stress (OS)-induced retinal damage as a primary contributor to AMD pathogenesis, prompting investigations into potential therapeutic interventions. Among the various nutrients studied for their potential in AMD risk reduction, antioxidants have shown promise, with initial findings from the Age-Related Eye Disease Study suggesting a correlation between antioxidant supplementation and decreased AMD progression. This article explores the scientific foundation supporting the therapeutic efficacy of tocotrienol-rich fraction (TRF) as a viable candidate for slowing AMD progression, based on interventional studies. AMD is characterized by OS, inflammation, dysregulated lipid metabolism, and angiogenesis, all of which TRF purportedly addresses through its potent anti-inflammatory, lipid-lowering, antiangiogenic, and antioxidant properties. The review underscores TRF's promising attributes, aiming to deepen understanding of AMD pathogenesis and advocate for TRF-based pharmacological interventions to enhance therapeutic outcomes. Given the pressing need for effective AMD treatments, TRF represents a promising avenue for intervention, offering hope for improved vision outcomes and enhanced quality of life for individuals affected by this debilitating condition.
随着全球人口老龄化，年龄相关性黄斑变性（AMD）对老年人的视觉健康构成了重大威胁，因此迫切需要采取预防措施。广泛的研究表明，氧化应激（OS）诱导的视网膜损伤是AMD发病机制的主要因素，这促使人们对潜在的治疗干预措施进行研究。在研究的各种具有降低AMD风险潜力的营养素中，抗氧化剂显示出了前景，年龄相关性眼病研究的初步结果表明，补充抗氧化剂与AMD进展减缓之间存在关联。本文基于干预性研究，探讨了支持富含生育三烯酚组分（TRF）作为减缓AMD进展的可行候选物的治疗效果的科学依据。AMD的特征是OS、炎症、脂质代谢失调和血管生成，据称TRF通过其强大的抗炎、降脂、抗血管生成和抗氧化特性来解决所有这些问题。该综述强调了TRF的有前景的特性，旨在加深对AMD发病机制的理解，并倡导基于TRF的药物干预以提高治疗效果。鉴于对有效治疗AMD的迫切需求，TRF是一个有前景的干预途径，为受这种使人衰弱的疾病影响的个体改善视力结果和提高生活质量带来了希望。
